Arlington Trust’s Novo Nordisk NVO Stock Holding History

Arlington Trust’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.44K	Hold	197	–	–	﹤0.01%	479
2026 Q1	$7.24K	Buy	+197	New	+$9.33K	﹤0.01%	478
2025 Q4	–	Sell	-2,490	Closed	-$138K	–	572
2025 Q3	$138K	Buy	2,490 +1,372	+123%	+$80.3K	0.02%	228
2025 Q2	$77.2K	Hold	1,118	–	–	0.02%	300
2025 Q1	$77.6K	Hold	1,118	–	–	0.02%	305
2024 Q4	$96.2K	Hold	1,118	–	–	0.02%	272
2024 Q3	$133K	Hold	1,118	–	–	0.03%	218
2024 Q2	$160K	Hold	1,118	–	–	0.04%	181
2024 Q1	$144K	Hold	1,118	–	–	0.04%	175
2023 Q4	$116K	Sell	1,118 -30,234	-96%	-$2.99M	0.03%	204
2023 Q3	$2.85M	Buy	+31,352	New	+$2.76M	1.17%	26

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Arlington Trust's NVO Position: Q2 2026 in Review

Arlington Trust held its Novo Nordisk (NVO) position steady in Q2 2026 at 197 shares worth $9.44K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

Arlington Trust first reported a position in NVO in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.85M in Q3 2023. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Arlington Trust held 197 shares of Novo Nordisk worth $9.44K as of Q2 2026.
Arlington Trust left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #479 holding.
Arlington Trust first reported a position in Novo Nordisk in Q3 2023 and has held it in 11 quarters since.
Arlington Trust's Novo Nordisk position peaked at $2.85M in Q3 2023.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.